{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011473","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.283870+00:00","generated_at":"2026-05-17T13:25:00.792774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xilio Q2 net loss $15.8M, cash $121.6M; pipeline progress on vilastobart and masked T cell engagers","bullets":["Net loss $15.8M in Q2 2025 vs $13.9M a year ago; cash and equivalents $121.6M vs $55.3M at Dec 31, 2024.","Vilastobart Phase 2 data at ASCO: 26% objective response rate in heavily pre-treated MSS CRC patients without liver metastases.","On track to nominate first development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) in H2 2025.","June 2025 follow-on offering raised ~$50M gross; up to $100M additional from warrants if exercised at $0.75 per share.","Cash runway expected through end of Q3 2026 based on current plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011473","json":"https://secwatch.observer/filing/0001558370-25-011473.json","markdown":"https://secwatch.observer/filing/0001558370-25-011473.md","text":"https://secwatch.observer/filing/0001558370-25-011473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/0001558370-25-011473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/xlo-20250814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:25:00.792774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}